

Clinical Endocannabinoid Deficiency and Cognitive Continuity: A Longitudinal Case Study Challenging the Neurodegeneration Paradigm

David A. Dawson *

Department of Research, Publication, & Education, AMCANN, LLLP (Independent Research Organization), Murrieta, California, USA.

World Journal of Biological and Pharmaceutical Research, 2025, 09(02), 020-033

Publication history: Received on 18 November 2025; revised on 23 December 2025; accepted on 26 December 2025

Article DOI: <https://doi.org/10.53346/wjbpr.2025.9.2.0025>

Abstract

Despite expanding acceptance of cannabis for medicinal use, empirical literature remains sparse regarding the long-term mental and neurobiological outcomes of continuous cannabis exposure over several decades. This self-case study examines the psychobiological trajectory of a biomolecular psychologist who has used cannabis intermittently since the 1970s and therapeutically since 2010 to manage polypharmacy withdrawal, opioid dependence, and psychiatric symptoms. The analysis integrates self-observational data, neurocognitive assessments, pharmacological history, and psychosocial context to evaluate outcomes on affect regulation, cognitive performance, neuroplasticity, and motivation. The case challenges persistent assumptions of irreversible cannabis-induced cognitive decline and supports the hypothesis that sustained cannabinoid modulation may promote neural resilience when employed within a biomolecularly informed framework. Findings are illustrative and intended to generate testable hypotheses rather than establish causality.

Keywords: Endocannabinoid system; Cannabinoids; Psychoneuroimmunology; Neuroadaptive Resilience; Longitudinal Case Study; Clinical Endocannabinoid Deficiency (CECD); Cannabinoid Homeostasis

1. Introduction

For more than half a century, the United States has maintained one of the most comprehensive prohibitions on biological cannabinoid research in modern science. The enactment of the Controlled Substances Act in 1970 [1] effectively silenced the empirical study of the plant *Cannabis sativa* and its naturally occurring cannabinoids, leaving a void in scientific understanding that has persisted for decades. The policy was founded less on biomedical evidence than on sociopolitical ideology—a moral policy of addiction that conflated psychoactivity with deviance. By classifying naturally occurring cannabinoids as Schedule I substances, federal policy positioned them alongside heroin and LSD, asserting “no accepted medical use and a high potential for abuse” [2]. Consequently, generations of scientists were restricted from exploring naturally occurring cannabinoids’ molecular, neurobiological, and psychopharmacological functions.

1.1. Cannabis as a Biological Constant

While modern prohibition sought to erase the plant’s legitimacy, cannabis itself represents a biological constant—molecules with 12,500 years of medicinal use, abruptly vilified in the modern era [3]. Archaeological and historical records confirm its continuous application in treating pain, inflammation, convulsions, and psychological distress throughout diverse civilizations [4, 5]. Across that immense timeline, humans relied on the plant’s phytochemical complexity—its cannabinoids, terpenes, and flavonoids—to modulate physiological systems long before those systems were scientifically named. The endocannabinoid system (ECS), now recognized as one of the body’s principal

* Corresponding author: David A. Dawson

homeostatic regulators, mediates neural, immune, and endocrine balance [6]. Yet its formal discovery in the 1990s came paradoxically after half a century of federally enforced ignorance.

From a biomolecular perspective, cannabinoids act not as foreign intruders but as complementary ligands within a pre-existing molecular conversation between the human body and its endogenous signaling systems [7]. Their therapeutic potential lies not in chemical novelty but in biological familiarity—a fact consistently reaffirmed by modern neurobiological research despite legal obstruction.

1.2. Bridging Science and Experience

This case study presents a unique intersection of lived experience and empirical observation: the 45-year psychobiological record of a biomolecular psychologist who has used cannabis intermittently since 1976 and therapeutically since 2010. The longitudinal nature of this self-case allows for a rare view across historical, pharmacological, and neurocognitive boundaries. Each epoch of use reflects a distinct sociocultural and neurobiological context—from the stigmatized experimentation of the 1970s, through the opioid-dominated medical landscape of the 1990s and 2000s, to the contemporary period of scientific reintegration.

This study thereby situates an individual narrative within the broader trajectory of cannabinoid research suppression and reawakening. The author's professional immersion in biomolecular psychology and endocannabinoid quantification offers an unparalleled perspective: one that merges subjective experiential data with objective neurobiological insight. Such integration transforms the autobiographical account into a living dataset, tracing the interplay of cognition, emotion, and neurochemistry across decades of exposure, abstinence, and renewal.

1.3. Cannabinoid Modulation as a Biomolecular Adaptation

Drawing upon the author's doctoral research, the endocannabinoid system is here conceptualized as a biomolecular adaptation to chronic physiological and psychological stressors [8]. Within this framework, cannabinoid signaling is not a pathological intrusion but a homeostatic mechanism that maintains equilibrium under conditions of stress, injury, or neurochemical dysregulation.

Chronic activation of the hypothalamic–pituitary–adrenal (HPA) axis, persistent inflammation, or dopaminergic imbalance can lead to maladaptive outcomes—ranging from anxiety and affective disorders to neurodegeneration. Endocannabinoids and phytocannabinoids alike mitigate these responses by regulating synaptic transmission, dampening hyperexcitability, and modulating neuroimmune crosstalk [9, 10]. The biomolecular psychologist's sustained use of cannabinoids thus provides a living experiment in adaptive homeostasis: a long-term calibration between internal biochemistry and environmental stressors.

This view aligns with the expanding theory of endocannabinoid deficiency disorders, which proposes that insufficient endogenous cannabinoid signaling contributes to conditions such as migraine, fibromyalgia, irritable bowel syndrome, PTSD, and neuropathic pain [11]. The restoration of ECS tone through targeted cannabinoid supplementation may normalize neurotransmitter balance and foster neural resilience.

1.4. Purpose and Rationale

Despite increasing legalization and therapeutic recognition, longitudinal data on long-term cannabis users, particularly within cognitively demanding professional populations, remain virtually nonexistent. Most available research focuses on short-term cognitive performance, adolescent exposure, or substance-abuse contexts, often confounded by polydrug variables [12]. This study, therefore, fills a critical gap: an empirical and introspective documentation of one individual's psychobiological evolution across nearly five decades of botanic cannabinoid exposure.

The purpose of this case study is twofold. First, it challenges the persistent assumption that chronic cannabinoid use inevitably leads to cognitive decline or motivational impairment. Second, it reframes sustained cannabinoid modulation as a potential therapeutic and adaptive process, mediated by molecular mechanisms that have co-evolved with human physiology.

By integrating first-person longitudinal data with biomolecular theory, this work seeks to humanize cannabinoid research, emphasizing observation over ideology. The findings, while specific to a single subject, hold broad implications for psychopharmacology, behavioral medicine, and public health policy.

Ultimately, this paper aims to restore cannabinoids to their rightful scientific context: not as agents of moral panic, but as molecules of biological continuity and adaptive potential. The decades-long prohibition of cannabinoid research has obscured not only a plant, but an entire endogenous communication system critical to human resilience. Understanding this system and its interaction with both natural and synthetic cannabinoids offer a pathway toward personalized medicine and neurobiological restoration.

1.5. Neuroprotective and Psychoneuroimmunological Foundation

Emerging research over the past three decades has reframed the endocannabinoid system (ECS) not as a pharmacological curiosity but as a fundamental regulator of neuroprotection, synaptic plasticity, and psychoneuroimmunological balance. The ECS, comprising the endogenous ligands anandamide and 2-arachidonoylglycerol (2-AG), their metabolic enzymes, and the CB₁ and CB₂ receptors, serves as a homeostatic modulator within the central and peripheral nervous systems. This bidirectional signaling network maintains equilibrium under physiological and psychological stress, thereby dampening excitotoxicity, oxidative injury, and neuroinflammatory cascades [13].

Within neural tissue, cannabinoids exert cytoprotective effects through multiple convergent pathways. Activation of CB₁ receptors reduces excessive glutamate release and calcium influx, thereby preventing excitotoxic neuronal death. Simultaneously, CB₂ receptor stimulation modulates microglial activation and cytokine release, reducing neuroinflammation and secondary oxidative damage. These coordinated mechanisms—described as the “endocannabinoid tone”—illustrate the ECS’s role as a biochemical buffer system that preserves neuronal integrity [13].

Functional neuroimaging studies further substantiate these protective dynamics. Positron emission tomography (PET) and single-photon emission computed tomography (SPECT) have revealed ECS-mediated regulation of dopaminergic transmission within mesocorticolimbic and striatal pathways, regions central to motivation, reward, and cognitive resilience [14]. This modulation aligns with psychoneuroimmunological models of stress adaptation, wherein cannabinoid signaling attenuates hypothalamic-pituitary-adrenal (HPA) axis hyperactivity and reduces neuroinflammatory biomarkers associated with chronic stress and depressive states.

Taken together, these findings redefine cannabinoid molecules as integral components of the body’s adaptive defense network rather than exogenous disruptors. The ECS emerges as an interface linking neurobiology, immune response, and psychological regulation, a molecular convergence point for maintaining cognitive continuity across stress, disease, and time. This integrative framework provides the scientific foundation for the present longitudinal case study.

1.6. Gap in the Literature and Rationale for the Present Study

Despite the growing body of neurobiological and psychoneuroimmunological evidence supporting the therapeutic potential of cannabinoid modulation, a profound empirical void persists. This gap stems not from a lack of scientific interest but from a half-century of federal prohibition that rendered the biological study of cannabinoids inaccessible to most U.S. research institutions. When cannabis was legislatively confined to Schedule I status, it became scientifically untouchable, an anomaly in biomedical research wherein one of the body’s most extensive neuromodulatory systems was deemed illicit for investigation [1,2,15].

Consequently, most published findings since the 1970s have relied on short-term, observational, or animal studies, with longitudinal human data nearly absent. The result is an incomplete understanding of how sustained cannabinoid exposure interacts with neurocognitive stability, emotional regulation, and systemic homeostasis over time. Specifically, no empirical framework yet exists to explore *cognitive continuity*—the maintenance of cognitive and psychological integrity across decades of medicinal or habitual cannabinoid use. This deficit stands in stark contrast to the prevailing narrative that long-term cannabis use inevitably results in cognitive decline or motivational impairment [16].

In addition to the scientific omission, cultural stigmatization and regulatory suppression have obstructed the development of psychoneuroimmunological models that integrate the ECS within chronic disease management, particularly in cases involving neuropathic pain, autoimmune conditions, or post-traumatic stress. These conditions share a common pathophysiological denominator: dysregulated endocannabinoid tone and impaired feedback between immune, neurological, and psychological systems [17]. Yet, federal restrictions have systematically excluded such hypotheses from mainstream clinical trials, forcing the field to rely on anecdotal reports and non-standardized observations rather than controlled data.

This longitudinal case study aims to address that gap by documenting over four decades of continuous cannabinoid exposure within a single individual, spanning eras of prohibition, pharmaceutical dependency, and modern clinical

reintegration. By integrating biomolecular, psychopharmacological, and experiential perspectives, this study seeks to characterize the *adaptive* rather than degenerative outcomes of sustained cannabinoid modulation. The objective is not only to illustrate personal cognitive continuity but to recontextualize long-term cannabinoid use within a biologically coherent framework of homeostatic resilience and neuroimmune balance.

1.7. Translational Framework and Diagnostic Rationale

Emerging evidence from clinical, neurobiological, and biochemical studies continues to validate the endocannabinoid system (ECS) as a central homeostatic regulator, linking psychological, neurological, and immunological functions. Dysregulation of this network—manifesting as impaired synthesis, degradation, or receptor signaling of endocannabinoids—has been documented across a spectrum of chronic inflammatory, affective, and stress-related disorders. In parallel, advancements in psychoneuroimmunology have illuminated the reciprocal crosstalk between cytokine signaling, limbic circuitry, and hypothalamic–pituitary–adrenal (HPA) axis dynamics, each of which is modulated by ECS activity.

Quantifying endocannabinoid tone, therefore, offers a novel diagnostic avenue for identifying individuals at risk of endocannabinoid deficiency disorders. Objective measurement of endocannabinoid biomarkers may further clarify the molecular underpinnings of disorders such as fibromyalgia, post-traumatic stress disorder, and autoimmune dysregulation, where conventional pathophysiological models have failed to account for systemic psycho-neuroimmune interactions. By integrating biochemical quantification with psychophysiological assessment, this study aims to establish a translational framework to identify ECS dysregulation as both a diagnostic biomarker and a therapeutic target within chronic disease management paradigms.

2. Methodology

2.1. Study Design and Epistemological Framework

This investigation employs a single-subject longitudinal self-case study design, integrating retrospective and prospective data across multiple decades. The author serves as both investigator and subject, a structure selected intentionally to enable sustained, high-resolution observation of psychobiological variables that would be impractical or unethical to capture within traditional cohort designs over a comparable temporal span.

The study is hypothesis-generating and exploratory, not inferential. Its primary objective is to document patterns of cognitive continuity, affective regulation, and neuroadaptive stability associated with long-term exposure to botanic cannabinoids, and to situate these observations within established psychoneuroimmunological and endocannabinoid frameworks. No claims of population-level generalizability or causal inference are made.

This design draws methodological precedent from established traditions in psychobiography, longitudinal clinical case reporting, and autoethnographic neuroscience, while grounding interpretation in biomolecular psychology and contemporary endocannabinoid system science.

2.2. Subject Characteristics and Context

The subject is a biomolecular psychologist with sustained engagement in cognitively demanding professional activities, including academic research, scientific publication, and organizational leadership. Cannabis exposure occurred intermittently beginning in the 1970s and transitioned to structured therapeutic use starting in 2010. Across the observation period, the subject experienced multiple physiological and psychosocial stressors, including chronic neuropathic pain, prolonged opioid exposure, medication withdrawal, and significant occupational demands.

The subject's scientific training enabled systematic documentation of psychobiological variables, enhancing observational precision while simultaneously necessitating explicit safeguards against interpretive bias (addressed below).

2.3. Data Sources and Measures

2.3.1. Data Collection

Data were collected through a combination of self-observation logs, retrospective recall, clinical documentation, and standardized cognitive assessments performed periodically since 2010. Triangulation between subjective narrative, objective testing, and medical records ensured ecological validity while preserving the qualitative integrity inherent to

a self-case design. The methodology draws upon traditions in psychobiography and autoethnography but is grounded in biomolecular psychology, emphasizing measurable psychoneuroimmunological correlates.

2.3.2. Data Sources and Instruments

Self-Observation and Retrospective Reporting

The author maintained structured journals noting cannabis dosage, strain type (sativa, indica, hybrid, CBD-dominant), route of administration, and context of use. Observations included affective tone, sleep quality, cognitive focus, and social engagement, as well as reflections on motivation, creativity, and emotional regulation. Earlier decades (1970s–2000s) relied on reconstructed timelines informed by secondary records and corroborating historical documentation.

Neurocognitive and Psychological Assessment

Formal testing was conducted intermittently between 2010 and 2024 using standardized measures such as the Wechsler Adult Intelligence Scale (WAIS-IV), Trail Making Test (TMT), Beck Depression Inventory (BDI-II), and State-Trait Anxiety Inventory (STAI). Results were analyzed for intra-individual stability, cognitive drift, and executive functioning over time. Trends were compared with published normative age-adjusted data to identify deviations indicative of neurocognitive decline or resilience.

Pharmacological and Medical Records Review

Detailed pharmacological history was extracted from medical documentation spanning multiple decades, including prescription records during opioid-based pain management and subsequent cannabis substitution therapy. Data were used to map transitions between pharmacological classes (opioids, antidepressants, cannabinoids) and their psychobiological consequences.

Contextual and Sociocultural Correlates

External variables such as professional workload, stress exposure, and sociocultural climate were incorporated to contextualize cannabinoid use and its psychological outcomes. These factors provided an ecological framework for interpreting changes in cognition, mood, and neurophysiological adaptation.

2.3.3. Self-Observation and Longitudinal Documentation

Structured self-observation logs were maintained during the therapeutic period (2010–2024), documenting:

- Cannabinoid formulation, approximate dosage, and route of administration
- Temporal context of use
- Perceived effects on cognition, affect regulation, sleep, motivation, and stress response

Earlier decades (1970s–2000s) were reconstructed using retrospective recall informed by corroborating medical records, professional timelines, and contemporaneous documentation where available. These periods are interpreted descriptively rather than quantitatively.

2.4. Neurocognitive and Psychological Assessment

Standardized neuropsychological instruments were administered intermittently between 2010 and 2024, including:

- Wechsler Adult Intelligence Scale (WAIS-IV)
- Trail Making Test (TMT)
- Beck Depression Inventory-II (BDI-II)
- State-Trait Anxiety Inventory (STAI)

Results were evaluated for within-subject longitudinal stability, with performance interpreted relative to age-adjusted normative expectations. The analytic emphasis was on intra-individual consistency over time, not superiority or enhancement.

2.4.1. Pharmacological and Medical Record Review

Medical records were reviewed to construct a longitudinal pharmacological timeline, including periods of opioid-based pain management, antidepressant exposure, cessation phases, and cannabinoid substitution. These data were used to contextualize psychobiological changes rather than to establish direct pharmacodynamic causality.

2.4.2. Contextual and Environmental Variables

Professional workload, psychosocial stressors, and sociocultural context were incorporated to provide ecological validity and to mitigate oversimplified attribution of outcomes solely to cannabinoid exposure.

2.4.3. Data Integration and Analytical Approach

A mixed qualitative–quantitative synthesis was employed. Quantitative measures were summarized descriptively to identify longitudinal trends, while qualitative content analysis was used to extract recurring themes related to cognitive stability, affective regulation, and stress adaptation.

Interpretation was guided by psychoneuroimmunological and ECS-informed models, emphasizing mechanistic plausibility rather than outcome determinism. Reliability was supported through temporal triangulation, cross-referencing with objective records, and conservative interpretive thresholds.

2.4.4. Ethical and Positionality Considerations

Given the author–subject overlap, this study adopts an explicit positionality declaration. The dual role introduces potential for confirmation bias and selective interpretation; accordingly, conclusions are intentionally constrained to descriptive and theoretical domains. The absence of intervention on third parties and reliance on non-invasive, previously collected data place the study outside the scope of human-subjects experimentation requiring IRB oversight; nevertheless, ethical principles of transparency, restraint, and methodological humility were applied throughout.

2.5. Strengths and Limitations

2.5.1. Strengths

The principal strength of this study is its exceptional longitudinal depth, encompassing over five decades of psychobiological observation—a temporal scale rarely available in cannabinoid research. This duration allows examination of cognitive continuity across aging, pharmacological transitions, and sociopolitical eras, offering insights unattainable through short-term or cross-sectional designs.

A secondary strength lies in integrating lived experience with biomolecular expertise. The subject’s scientific training enabled structured documentation, nuanced interpretation, and alignment with established neurobiological mechanisms, enhancing ecological validity and theoretical coherence.

Finally, the study initiates a novel conceptual framework, reframing long-term cannabinoid exposure through adaptive homeostasis rather than neurodegenerative assumption, thereby generating testable hypotheses for future research.

2.5.2. Limitations

Several limitations must be acknowledged.

First, as a single-subject self-case study, findings are not generalizable and may not be interpreted as representative of broader populations. Observed associations cannot establish causality and may reflect individual biological variability.

Second, retrospective reconstruction of early decades introduces potential recall bias. Although mitigated through corroborating records and conservative interpretation, temporal precision is inherently limited for earlier epochs.

Third, the absence of direct physiological measures—such as quantified endocannabinoid levels, inflammatory biomarkers, or longitudinal neuroimaging—restricts mechanistic verification. The study, therefore, prioritizes psychobiological coherence over biochemical confirmation, a trade-off appropriate to its exploratory intent.

Finally, the author’s professional expertise, while enhancing interpretive depth, also introduces the possibility of theoretical confirmation bias. This risk is addressed through explicit acknowledgment, restrained claims, and reliance on peer-reviewed mechanistic literature rather than anecdotal inference.

2.5.3. Interpretive Boundary

This study should be understood as illustrative rather than definitive. Its value lies in illuminating a biologically plausible trajectory of cognitive continuity under sustained cannabinoid modulation, thereby informing future controlled, biomarker-integrated, longitudinal investigations.

2.6. Data Integration and Analysis

The data were analyzed using a mixed qualitative–quantitative framework. Descriptive statistics summarized cognitive test scores, affective measures, and usage patterns, while qualitative content analysis identified recurring themes related to self-regulation, motivation, and cognitive continuity. A psychoneuroimmunological interpretive lens guided the synthesis of findings, emphasizing the interaction between cannabinoid modulation, stress adaptation, and neuroimmune balance.

Reliability was supported through iterative self-verification, chronological triangulation, and cross-reference with objective records. Although limited by its single-subject scope, the design offers unparalleled longitudinal depth and mechanistic insight, aligning with emerging paradigms in personalized neuropsychopharmacology.

3. Results and Observations

To contextualize the psychobiological outcomes observed across this five-decade case study, a longitudinal summary of cannabis use epochs, associated physiological and psychological states, and adaptive outcomes is provided in Table 1. This structure establishes the temporal and functional trajectory through which cannabis transitioned from perceived recreational use to a biomolecular regulatory intervention. This tabular representation is essential for distinguishing the clinical and functional outcomes associated with each epoch, enabling clear visualization of adaptive mechanisms over time prior to detailed psychobiological analysis.

Table 1 Longitudinal Case Summary of Cannabis Use, Physiological Adaptation, and Cognitive Continuity (1976–Present)

Epoch	Years	Psychological Context	Cannabis Use Pattern	Formulation / Route	Observed Psychobiological Effects	Key Realizations
1. Introduction to Cannabis and Paradigm Disruption	1976–1981	Initial indoctrination into anti-cannabis ideology; discovery of cannabis through an academically gifted peer; emergence of curiosity and cognitive dissonance between propaganda and experience.	Intermittent use; perceived as recreational, though functionally analgesic for neuropathic pain.	Smoked flower; low THC, balanced cannabinoids.	Reduced neuropathic pain; mild euphoria; stable cognition.	Recognized disconnect between social narrative and personal observation—cannabis produced therapeutic benefit without cognitive deficit.
2. Academic Integration & Pharmacological Conditioning	1981–1989	Undergraduate molecular biology; graduate studies in science education; early teaching	Concurrent cannabis (moderate, social/academic) and prescribed opioids.	Smoked flower; oral codeine and other opiates.	Cannabis alleviated pain: opioids alleviated pain while inducing tolerance and dependence.	Began recognizing pharmacological imbalance. Cannabis stabilized function during

		career; conditioned by medical a model favoring opiates for neuropathic pain.				opioid deterioration.
3. Pharmacological Escalation & Cannabis Abstinence	1989–2006	Transition from academia to casino industry; drug-screened environment necessitated cannabis abstinence; complete reliance on opiates; biochemical and psychological decline culminating in stroke.	Cannabis abstinent; exclusive reliance on prescribed opioids.	Oral and transdermal opioids (multiple classes).	Progressive tolerance, sedation, vascular compromise, and 2006 ischemic stroke.	Realized that institutional protocols prioritized dependency over health; absence of endocannabinoid modulation correlated with system collapse.
4. Resurrection Through Cannabinoid Medicine	2006–2017	Left hospice against medical advice; initiated self-directed cannabinoid and terpene therapy; gradual physiological and cognitive recovery.	Daily medicinal use of botanic cannabinoids and terpenes.	Primary: Vaporization for daily therapeutic administration (preferred for its control and rapid onset). Occasional: Social use via smoked flower. Rare: Limited topical and tincture applications, with a single edible trial.	Alleviated opioid addiction, restored appetite, focus, and emotional balance.	Cannabis enabled neurochemical homeostasis; survival achieved through biochemical autonomy and restored ECS balance.
5. Biomolecular Revolution and Scientific Leadership	2018–Present	Doctoral researcher in biomolecular psychology; founder of AMCANN; ongoing quantification of the endocannabinoid system; published >12 peer-reviewed papers.	Controlled, research-guided cannabinoid and terpene use for cognition and neuropathic stability.	Strains high in α -pinene and CBD for focus and anti-inflammatory modulation.	Sustained cognitive sharpness, emotional stability, and creative output.	Transformed from patient to investigator; established a scientific theoretical framework for endocannabinoid deficiency disorders.

Note: ECS = Endocannabinoid system; HPA = Hypothalamic–pituitary–adrenal axis; BDNF = Brain-derived neurotrophic factor; THC = Δ9-tetrahydrocannabinol.

The longitudinal epochs summarized in Table 1 illustrate distinct phases wherein cannabis functioned as either a compensatory neurobiological agent, a therapeutic substitute for pharmacological dependence, or a targeted biomolecular intervention. These transitions provide a structured framework for interpreting psychobiological outcomes across time, thereby supporting the central hypothesis that botanic cannabinoids may sustain cognitive continuity through endocannabinoid homeostasis.

The following subsections expound upon each epoch in greater depth, presenting detailed neurocognitive, affective, and psychoneuroimmunological observations in alignment with endocannabinoid modulation and adaptive neurobiological function.

3.1. Cognitive Continuity Across Decades

Over the course of more than five decades of intermittent and therapeutic cannabis use, no evidence of progressive cognitive decline was observed. Standardized assessments conducted between 2010 and 2024 revealed consistent performance across domains of verbal comprehension, working memory, and perceptual reasoning, with minor fluctuations attributable to fatigue and situational stress rather than cannabis exposure. Executive functioning remained intact, as demonstrated by stable Trail Making Test (TMT) completion times and preserved attentional flexibility.

Contrary to prevailing assumptions of cannabis-induced amotivation or diminished executive capacity, the subject maintained a career requiring sustained intellectual engagement, advanced research design, and high levels of analytical reasoning. Qualitative observation corroborated this: extended writing projects, peer-reviewed publications, and complex organizational management tasks were performed without measurable cognitive regression. These findings suggest the maintenance of cognitive continuity, defined here as the preservation of functional intellect and adaptive problem-solving capacity across decades of cannabinoid exposure.

3.2. Affective Regulation and Emotional Stability

Self-report journals and psychological inventories indicated improved emotional regulation during periods of therapeutic cannabis use compared to prior pharmacological interventions. Cannabis was associated with decreased symptom severity related to anxiety, intrusive rumination, and depressive affect, particularly following opioid withdrawal.

Mood stabilization appeared linked to reduced hypothalamic–pituitary–adrenal (HPA) axis hyperactivity and enhanced affective flexibility. The subject reported fewer episodes of emotional blunting or apathy, common during selective serotonin reuptake inhibitor (SSRI) therapy, and greater subjective capacity for empathy and reflective insight. These trends support hypotheses that cannabinoid signaling may restore homeostatic affective balance through neuromodulation of serotonergic and endocannabinoid pathways.

3.3. Neuroadaptive Responses and Resilience

Long-term observation suggests that sustained cannabinoid modulation may promote neuroadaptive resilience, mitigating the maladaptive stress responses characteristic of chronic neurochemical dysregulation. Over successive decades, the subject experienced periods of extreme psychosocial stress and physiological insult, including pain syndromes and medication withdrawal. Despite these challenges, no evidence of neurodegenerative symptomatology, cognitive erosion, or psychotic features emerged.

Subjective reports describe heightened adaptability, faster recovery from stressors, and improved sleep regulation with cannabinoid therapy. These findings align with existing research indicating that cannabinoid-mediated reduction of glutamatergic excitotoxicity and neuroinflammation supports neuronal preservation and synaptic remodeling. Within a psychoneuroimmunological framework, the observed stability reflects the ECS's capacity to maintain systemic equilibrium under prolonged environmental and internal stressors.

3.4. Motivation, Productivity, and Psychosocial Functioning

Throughout the study period, professional productivity and goal-directed behavior remained robust. Rather than the stereotyped 'amotivational syndrome' a hypothesis that some longitudinal and cross-sectional studies have supported [18,19], cannabis use in this case was often temporally associated with increased creative output and sustained focus

during extended research and writing sessions. Moreover, more recent and methodologically rigorous investigations challenge the generalizability of amotivational effects [20,21].

The subject reported that specific strains rich in limonene and pinene enhanced cognitive fluency and working memory, while those with higher myrcene content promoted relaxation and sleep regulation. Importantly, use patterns evolved from unstructured, recreational contexts in early decades to deliberate, therapeutic, and strain-targeted administration in later years. This shift coincided with improvements in self-regulation, work efficiency, and overall psychosocial functioning.

3.5. Summary of Findings

Across five decades of observation, cumulative data reveal a trajectory of psychobiological adaptation rather than deterioration. Sustained cannabinoid modulation, when applied with biomolecular awareness and intentionality, appears compatible with long-term cognitive health, affective stability, and neuroimmune resilience.

These results challenge the conventional narrative of inevitable cannabis-induced cognitive decline and suggest that, within specific physiological and psychological parameters, cannabinoid use may act as an adaptive mechanism—supporting homeostasis rather than disrupting it.

3.6. Methodological Strengths, Constraints, and Interpretive Scope

The findings presented here, while grounded in decades of observation, must be interpreted within the methodological context of a single-subject case design. The study's greatest strength lies in its extraordinary longitudinal depth, spanning more than five decades of continuous psychobiological documentation. This temporal range offers a uniquely comprehensive view of sustained cannabinoid modulation across major social, pharmacological, and neurobiological eras, a historical continuum rarely captured in cannabinoid research.

Equally significant is the author's dual perspective as both subject and biomolecular psychologist. This rare vantage point enables the integration of introspective self-observation, clinical data, and psychometric assessment within a coherent theoretical framework. The combination of firsthand experience and scientific literacy lends interpretive precision and enhances ecological validity. It also allows for the articulation of mechanistic hypotheses grounded in both personal phenomenology and biomolecular evidence, something traditional cohort studies are ill-equipped to achieve.

Nonetheless, several limitations warrant consideration. As a self-case study, the potential for recall bias, selective interpretation, and introspective subjectivity cannot be eliminated, despite the use of structured journaling and triangulation with objective data. Retrospective reconstruction of early decades introduces the possibility of temporal distortion. Furthermore, the absence of comparison subjects limits generalizability, and causal attributions between cannabis use and observed outcomes must remain inferential rather than definitive.

Physiological verification of endocannabinoid tone, such as through biochemical quantification or neuroimaging, was beyond the scope of this investigation. While future studies may integrate such measures, the current design prioritizes experiential depth and psychobiological coherence over laboratory precision. Finally, while professional expertise strengthens the interpretive process, it may also introduce confirmation bias toward biologically integrative explanations of observed stability.

In acknowledging these boundaries, the study preserves both its integrity and its intent: not to generalize, but to illuminate one individual's longitudinal interaction with a class of molecules that mirror the body's own biochemical language. Within that framework, the observations remain both scientifically and humanly instructive.

4. Discussion

4.1. Reframing Long-Term Cannabis Use Through Endocannabinoid Homeostasis

The results of this case study challenge prevailing narratives that long-term botanic cannabinoid exposure inevitably results in cognitive or motivational decline. Instead, the findings align with contemporary models positioning the endocannabinoid system (ECS) as a central regulator of neurobiological resilience, responsible for maintaining synaptic plasticity, emotional equilibrium, and adaptive stress responses [13,17]. The preservation of cognitive continuity and affective stability over more than five decades of cannabinoid interaction suggests that exogenous cannabinoids, when used with biomolecular awareness, may support rather than disrupt endocannabinoid tone.

Clinical endocannabinoid deficiency (CECD), first articulated by Russo and later expanded through functional neuroimaging and cerebrospinal fluid studies, proposes that insufficient endogenous cannabinoid signaling contributes to disorders characterized by chronic pain, anxiety, affective dysregulation, and impaired stress adaptation [17]. The subject's trajectory, marked by improved affective regulation and neuroadaptive response following therapeutic cannabinoid use, provides phenomenological support for this model. Rather than producing cognitive erosion, long-term cannabinoid exposure appears to have compensated for underlying dysregulation, functioning as a biomolecular adaptation to chronic physiological and psychological stressors.

4.2. Neuroprotection and Adaptive Plasticity

The observed maintenance of executive function over decades is consistent with evidence that activation of CB₁ and CB₂ receptors plays a neuroprotective role through the reduction of glutamatergic excitotoxicity and inhibition of neuroinflammatory cascades [13]. Although cannabinoid exposure is often reduced to its psychoactive effects in public discourse, the ECS's fundamental biological role is homeostatic restoration. In the context of this case, sustained botanic cannabinoid use appears to have facilitated long-term synaptic maintenance and emotional resilience, a finding that aligns with preclinical data demonstrating botanic cannabinoid-mediated promotion of neural plasticity under conditions of chronic stress.

Additionally, the absence of neurodegenerative indicators or psychotic features contrasts sharply with the predominant perception of cannabis as a neurotoxic agent. Instead, the psychobiological trajectory observed supports a model of adaptive modulation, wherein exogenous cannabinoids serve as functional analogues to endogenous signaling molecules to maintain neuronal viability across the lifespan.

4.3. Motivation and Psychosocial Functioning in Context

While traditional literature has proposed an "amotivational syndrome" associated with chronic cannabis use [18,19], more recent evidence disputes the universality of this phenomenon, attributing decreased motivation to confounding variables such as depression, psychosocial instability, or adolescent-onset exposure rather than cannabis itself [20,21]. In this study, cannabis use was associated with heightened creativity, increased productivity, and sustained engagement in complex intellectual and professional activities. This suggests that context, intention, and biological individuality are critical determinants of outcome—factors often omitted in generalized models that assume uniform responses to cannabinoid exposure.

The subject's progression from unstructured recreational use to deliberate, strain-specific therapeutic use parallels contemporary trends in precision cannabinoid medicine. This evolution may explain the enhancement rather than suppression of motivational states in later decades, supporting the hypothesis that cannabinoids can facilitate self-regulation when aligned with underlying biological need and administered within a psychobiological framework.

4.4. Psychoneuroimmunological Mechanisms of Cannabinoid Action

A growing body of evidence demonstrates that cannabinoid signaling functions at the interface of the nervous, immune, and endocrine systems, acting as a regulatory network that maintains psychobiological homeostasis [9,22]. The endocannabinoid system (ECS) modulates physiological responses to stress through a coordinated mechanism that regulates neurotransmitter release, immune activation, and hormonal feedback. This integrated control suggests that cannabinoids are not exogenous disruptors, but rather biomolecular agents capable of restoring internal equilibrium in the presence of chronic physiological dysregulation.

4.5. Modulation of HPA Axis Function

The hypothalamic–pituitary–adrenal (HPA) axis is a central mediator of the stress response. Dysregulated HPA activity is associated with anxiety, depression, autoimmune activation, and chronic pain syndromes [23,24]. Cannabinoid receptor activation, particularly CB₁ receptors in the hypothalamus and limbic regions, has been shown to downregulate corticotropin-releasing hormone (CRH) and reduce systemic cortisol secretion [24,26]. This inhibitory control promotes autonomic balance and reduces the neurotoxic effects of prolonged stress signaling.

4.6. Immune and Cytokine Regulation

CB₂ receptor activation on immune cells suppresses proinflammatory cytokines such as interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF- α), while promoting anti-inflammatory mediators such as IL-10 [25,26,27,28]. This immune regulatory mechanism is critical in preventing chronic inflammation, a driver of neuropathic pain, mood disorders, and

autoimmune dysregulation. The subject's long-term resilience in the presence of previously destabilizing physiological stressors is consistent with cannabinoid-mediated immunomodulation.

4.7. Neuroprotective and Synaptic Adaptation Effects

Cannabinoid signaling reduces glutamate-induced excitotoxicity, enhances neurogenesis, and promotes synaptic remodeling through brain-derived neurotrophic factor (BDNF) pathways [22]. These neuroadaptive functions help maintain cognitive stability and emotional regulation across the lifespan. In this case, decades of cannabinoid interaction corresponded with preserved neurocognitive performance and absence of neurodegenerative indicators, aligning with preclinical findings of cannabinoid-mediated neural resilience.

4.8. Integrated Psychoneuroimmune Homeostasis

Taken together, these mechanisms demonstrate that cannabinoids operate within a unified psychoneuroimmunological framework, facilitating homeostatic regulation across interdependent biological systems. Rather than impairing physiological function, long-term cannabinoid modulation in this subject appears to have supported *allostatic recalibration*: the restoration of optimal internal stability in response to chronic external and internal stressors.

5. Conclusion

This five-decade longitudinal case study provides a rare and informative window into the long-term psychobiological effects of sustained botanic cannabinoid use within a cognitively demanding professional context. Contrary to prohibition-era narratives that associate chronic cannabis exposure with cognitive decline, emotional dysregulation, and motivational impairment, the findings of this investigation demonstrate a trajectory of preserved neurocognitive integrity, stabilized affective functioning, and enhanced adaptive resilience. These outcomes are consistent with contemporary psychoneuroimmunological models in which the endocannabinoid system operates as a central regulator of homeostatic equilibrium across neural, immune, and endocrine domains.

The subject's sustained interaction with botanic cannabinoids appears not to have disrupted neurobiological processes, but rather to have supported the restoration and maintenance of endocannabinoid tone in response to chronic physiological and psychological stressors. Such findings lend phenomenological support to the theory of clinical endocannabinoid deficiency (CECD) and suggest that cannabinoids may function as biomolecular adaptogens—compounds that promote systemic stability by modulating dysregulated signaling pathways.

While limited by its single-subject design, the unparalleled temporal scope and mechanistic insight of this case challenge reductionist interpretations of cannabis as a neurotoxic agent. Instead, this work offers a framework for reconceptualizing long-term cannabinoid use through the lens of biomolecular psychology, emphasizing individualized adaptation over generalized pathology. The results underscore the need for further longitudinal research and endocannabinoid-based diagnostic approaches that acknowledge biological diversity, psychoneuroimmune interactions, and the therapeutic potential of targeted cannabinoid modulation.

Ultimately, this study restores cannabis to its rightful place within the continuum of human biological evolution—not as an exogenous disruptor, but as a botanical molecule interacting with an intrinsic physiological system designed to maintain cognitive continuity, emotional equilibrium, and neural resilience across the lifespan.

5.1. Future Directions

This case study highlights the urgent need for longitudinal, mechanistically informed research that moves beyond short-term observational models and prohibition-era assumptions. The outcomes observed over five decades of sustained botanic cannabinoid interaction underscore the importance of developing research frameworks that integrate endocannabinoid tone, psychoneuroimmune dynamics, and biopsychological adaptation.

Future investigations should prioritize the following directions:

5.1.1. Biomarker-Based Quantification of Endocannabinoid Tone

Advances in liquid chromatography–mass spectrometry (LC-MS/MS) now enable direct quantification of circulating endocannabinoids and related lipid mediators. Establishing normative endocannabinoid reference ranges across populations will be critical for identifying individuals with endocannabinoid deficiency disorders and assessing therapeutic outcomes with precision.

5.1.2. Longitudinal Human Studies in Cognitively Demanding Professions

There is a complete absence of data examining the long-term botanic cannabinoid use in high-functioning, cognitively intensive populations. Systematic longitudinal trials—incorporating neurocognitive assessment, neuroimmune biomarkers, and functional neuroimaging—are essential to determine trajectories of resilience versus decline under sustained cannabinoid modulation.

5.1.3. Psychoneuroimmunological Modeling of Cannabinoid Adaptation

Future research should employ integrated models that capture cannabinoid effects across neural, immune, and endocrine pathways. This includes assessing the impact of cannabinoids on HPA axis regulation, cytokine expression, oxidative stress reduction, and synaptic plasticity. Mechanistic studies can clarify how cannabinoids function as adaptogens under chronic stress conditions.

5.1.4. Precision Cannabinoid Medicine

This case illustrates the therapeutic significance of strain-specific cannabinoid and terpene profiles. Controlled clinical studies examining the differential effects of phytochemical composition on cognition, mood regulation, and inflammation are needed to guide personalized treatment protocols.

5.1.5. Policy Reform and Clinical Integration

Finally, the findings support re-evaluation of regulatory frameworks that classify botanic cannabinoids as neurotoxic substances. There is a scientific and ethical imperative to integrate endocannabinoid assessment into clinical practice, allowing individualized cannabinoid-based interventions to be developed in accordance with measurable physiological need rather than ideological constraint.

5.1.6. Closing Statement

The present case study is not an endpoint, but a beginning—a foundational model for understanding botanic cannabinoids through the lens of biomolecular adaptation rather than prohibitionist myth. The implications extend beyond a single individual to the future of personalized medicine, neuroimmune health, and our evolving relationship with one of humanity's oldest biological allies.

Compliance with ethical standards

Disclosure of conflict of interest

The author declares no conflict of interest.

References

- [1] Ortiz D, Preuss C. The Controlled Substances Act and the political weaponization of drug policy: A historical review of the Bureau of Narcotics and Dangerous Drugs and the Nixon Administration. *J Hist Policy Res.* 2022;14(3):41-55.
- [2] United States Drug Enforcement Administration. Controlled Substances Act: Drug scheduling definitions and criteria. *Federal Register.* 2017;82(192):46355-46357.
- [3] Russo EB. History of cannabis as medicine: From ancient roots to modern resurgence. *J Cannabis Ther.* 2007;7(1):3-14.
- [4] Zuardi AW. Cannabidiol: From an inactive cannabinoid to a drug with wide spectrum of action. *Rev Bras Psiquiatr.* 2008;30(3):271-80.
- [5] Russo EB, Jiang HE, Li X, Sutton A, Carboni A, Del Bianco F, Mandolino G, Potter DJ, Zhao YX, Bera S, Zhang YB, Lü EG, Ferguson DK, Hueber F, Zhao LC, Liu CJ, Wang YF, Li CS. Phytochemical and genetic analyses of ancient cannabis from Central Asia. *J Exp Bot.* 2008;59(15):4171-82.
- [6] Di Marzo V, Bifulco M, De Petrocellis L. The endocannabinoid system and its therapeutic exploitation. *Nat Rev Drug Discov.* 2004;3(9):771-84.
- [7] Mechoulam R, Hanuš LO. The discovery of endocannabinoids and the origins of cannabinoid research. *Chem Phys Lipids.* 2002;121(1-2):23-41.

- [8] Dawson DA. *Structural Stigmatization of Medicinal Botanic Cannabinoid Use: An Interpretative Phenomenological Analysis*. Doctoral Dissertation. San Diego (CA): National University; 2024. Available from: Academia.edu and Scopus.
- [9] Pacher P, Bátkai S, Kunos G. The endocannabinoid system as an emerging target of pharmacotherapy. *Pharmacol Rev*. 2006;58(3):389–462.
- [10] Cabral GA, Griffin-Thomas L. Emerging role of the cannabinoid receptor CB2 in immune regulation: Therapeutic prospects for neuroinflammation. *Expert Rev Mol Med*. 2009;11:e3.
- [11] Russo EB. Clinical endocannabinoid deficiency (CECD): Can this concept explain therapeutic benefits of cannabis in migraine, fibromyalgia, irritable bowel syndrome and other treatment-resistant conditions? *Neuro Endocrinol Lett*. 2008;29(2):192–200.
- [12] Meier MH, Caspi A, Ambler A, Harrington H, Houts R, Keefe RSE, et al. Persistent cannabis users show neuropsychological decline from childhood to midlife. *Proc Natl Acad Sci USA*. 2012;109(40):E2657–E2664.
- [13] **van der Stelt M, Di Marzo V**. Cannabinoid receptors and their role in neuroprotection. *Trends Pharmacol Sci*. 2003;24(10):563–569.
- [14] Bloomfield MAP, Ashok AH, Volkow ND, Howes OD. The effects of Δ^9 -tetrahydrocannabinol on the dopamine system. *Nature*. 2016;539(7629):369–377.
- [15] **Volkow ND, Baler RD, Compton WM, Weiss SR**. Adverse health effects of marijuana use. *N Engl J Med*. 2014;370(23):2219–2227.
- [16] Broyd SJ, van Hell HH, Beale C, Yücel M, Solowij N. Acute and chronic effects of cannabinoids on human cognition—A systematic review. *Biol Psychiatry*. 2016;79(7):557–567.
- [17] Russo EB. Clinical endocannabinoid deficiency reconsidered: current research supports the theory in migraine, fibromyalgia, irritable bowel, and other treatment-resistant syndromes. *Cannabis Cannabinoid Res*. 2016;1(1):154–165.
- [18] Lac A, Luk JW. Testing the amotivational syndrome: Marijuana use longitudinally predicts lower self-efficacy even after controlling for demographics, personality, and alcohol and cigarette use. *Psychology of Addictive Behaviors*. 2018;32(7):740–751. doi:10.1037/adb0000394.
- [19] Petrucci AS, Mokrysz C, Lawn W, Freeman TP, Curran HV. A comprehensive examination of the links between cannabis use and motivation. *Psychopharmacology (Berl)*. 2020;237(10):3097–3110. doi:10.1007/s00213-020-05604-0.
- [20] Pacheco-Colón I, Coxe S, Podrebarac SK, Gonzalez R. Longitudinal associations between cannabis use and motivation in adolescents. *Frontiers in Psychology*. 2021;12:689348. doi:10.3389/fpsyg.2021.689348.
- [21] Inzlicht M, Shenhav A, Andrews NE, van der Linden M. Chronic cannabis use in everyday life: Emotional, motivational, and self-regulatory effects. *Social Psychological and Personality Science*. 2024;15(2):248–259. doi:10.1177/19485506241245744.
- [22] Hillard CJ. Stress regulates endocannabinoid signaling. *Neuropsychopharmacology*. 2014;39(1):204–205. doi:10.1038/npp.2013.215.
- [23] Finn DP. Endocannabinoids and the HPA axis: an axis within an axis. *Br J Pharmacol*. 2010;160(2):284–285. doi:10.1111/j.1476-5381.2010.00789.x.
- [24] McEwen BS. Protective and damaging effects of stress mediators: central role of the brain. *Dialogues Clin Neurosci*. 2006;8(4):367–381.
- [25] Patel S, Hillard CJ. Adaptations in endocannabinoid signaling in response to repeated homotypic stress: a mechanism for stress habituation. *Eur J Neurosci*. 2008;27(11):2821–2829. doi:10.1111/j.1460-9568.2008.06266.x.
- [26] Romero-Sandoval EA, Kolano AL, Alvarado-Vázquez PA. Cannabis and cannabinoids for chronic pain. *Curr Rheumatol Rep*. 2017;19(11):67. doi:10.1007/s11926-017-0693-1.
- [27] Nagarkatti P, Pandey R, Rieder SA, Hegde VL, Nagarkatti M. Cannabinoids as novel anti-inflammatory drugs. *Future Med Chem*. 2009;1(7):1333–1349. doi:10.4155/fmc.09.93.
- [28] Campolongo P, Trezza V, Cassano T, Gaetani S, Morgese MG, Cuomo V. Cannabinoids and neurogenesis: potential therapeutic implications. *Neurotox Res*. 2009;15(3):243–257.